Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 5074

Sort by

Sort Order Select

Journal Articles

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani

Blood (2021) 138 (9): 749–757.

https://doi.org/10.1182/blood.2021010764

Published: 2021

Journal Articles

Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing

Elisabeth Ehrend, Patricia Manns, Sabine Harenkamp, Erhard Seifried, Christof Geisen, Halvard Bonig

Blood (2021) 138 (9): 814–817.

https://doi.org/10.1182/blood.2021011396

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Activated protein C has a regulatory role in factor VIII function

Amelia R. Wilhelm, Nicole A. Parsons, Benjamin J. Samelson-Jones, Robert J. Davidson, Charles T. Esmon, Rodney M. Camire, Lindsey A. George

Blood (2021) 137 (18): 2532–2543.

https://doi.org/10.1182/blood.2020007562

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Blood (2021) 137 (16): 2231–2242.

https://doi.org/10.1182/blood.2020009217

Published: 2021

Includes: Supplemental data

Journal Articles

Tolerogenic anti–IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity

Qingxiao Song, Xiaoning Wang, Xiwei Wu, Hanjun Qin, Yingfei Li, Arthur D. Riggs, Paul J. Martin, Yuan-Zhong Chen, Defu Zeng

Blood (2021) 137 (16): 2243–2255.

https://doi.org/10.1182/blood.2020006345

Published: 2021

Includes: Supplemental data

Journal Articles

Preclinical efficacy of humanized, non–FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia

Christine Tran Quang, Benedetta Zaniboni, Romain Humeau, Etienne Lengliné, Marie Emilie Dourthe, Rajkumar Ganesan, Sanjaya Singh, Justin M. Scheer, Vahid Asnafi, Jacques Ghysdael

Blood (2020) 136 (11): 1298–1302.

https://doi.org/10.1182/blood.2019003801

Published: 2020

Includes: Supplemental data

Journal Articles

FcRn augments induction of tissue factor activity by IgG-containing immune complexes

Douglas B. Cines, Sergei Zaitsev, Lubica Rauova, Ann H. Rux, Victoria Stepanova, Sriram Krishnaswamy, Amrita Sarkar, M. Anna Kowalska, Guohua Zhao, Alan E. Mast, Laurence J. Blumberg, Keith R. McCrae, Mortimer Poncz, Jonathan J. Hubbard, Michal Pyzik, Richard S. Blumberg

Blood (2020) 135 (23): 2085–2093.

https://doi.org/10.1182/blood.2019001133

Published: 2020

Includes: Supplemental data

Journal Articles

The TEMPI syndrome

David B. Sykes, Casey O’Connell, Wilfried Schroyens

Blood (2020) 135 (15): 1199–1203.

https://doi.org/10.1182/blood.2019004216

Published: 2020

Includes: Supplemental data

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis

Kandace Gollomp, Amrita Sarkar, Sanjiv Harikumar, Steven H. Seeholzer, Gowthami M. Arepally, Kristin Hudock, Lubica Rauova, M. Anna Kowalska, Mortimer Poncz

Blood (2020) 135 (10): 743–754.

https://doi.org/10.1182/blood.2019002329

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang Zhu, Robert H. Blum, Ryan Bjordahl, Svetlana Gaidarova, Paul Rogers, Tom Tong Lee, Ramzey Abujarour, Gregory B. Bonello, Jianming Wu, Pei-Fang Tsai, Jeffrey S. Miller, Bruce Walcheck, Bahram Valamehr, Dan S. Kaufman

Blood (2020) 135 (6): 399–410.

https://doi.org/10.1182/blood.2019000621

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

Mounica Vallurupalli, Nancy Berliner

Blood (2019) 134 (21): 1783–1786.

https://doi.org/10.1182/blood.2019002289

Published: 2019

Journal Articles

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome in Pregnancy: A Single Center Retrospective Review

Pallavi Kopparthy, MD, Anita Rajasekhar, MD

Blood (2019) 134 (Supplement_1): 4899.

https://doi.org/10.1182/blood-2019-131846

Published: 2019

Journal Articles

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

Jason G Underwood, PhD BA, Jenny L. Smith, MSc, MD, Lindsey F. Call, B.A., Elizabeth Tseng, PhD, Tiffany A. Hylkema, BS, Rhonda E. Ries, MA, Amanda R. Leonti, MS, Jason E. Farrar, MD, Timothy Junius Triche, Jr., PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 4658.

https://doi.org/10.1182/blood-2019-131508

Published: 2019

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

CD4 + T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism

Matteo Bellone, MD, Paolo Dellabona, MD PhD, Arianna Calcinotto, BS, Giulia Casorati, PhD, Alessandra Rovida, PhD, Maria Teresa Sabrina Bertilaccio, PhD, Elena Cattaneo, Matteo Grioni, Federico caligaris-Cappio, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 683.

https://doi.org/10.1182/blood-2019-128246

Published: 2019

Journal Articles

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Charles C. Chu, PhD, Jonathan J. Pinney, MS, Karl R. VanDerMeid, BS, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Michael Rusty Elliott, PhD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 682.

https://doi.org/10.1182/blood-2019-124901

Published: 2019

NARROW

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Activated protein C has a regulatory role in factor VIII function

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Tolerogenic anti–IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity

Preclinical efficacy of humanized, non–FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia

FcRn augments induction of tissue factor activity by IgG-containing immune complexes

The TEMPI syndrome

A complementary new drug for PNH

Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome in Pregnancy: A Single Center Retrospective Review

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

CD4 + T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only